跳至主要内容
临床试验/NCT01670396
NCT01670396Unknown不适用

G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents

Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2012年3月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
300
试验地点
1
主要终点
In-stent restenosis

研究概览

简要总结

The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

详细描述

Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who underwent follow-up angiography. All the patients must had been implanted with DES during the last two years.

排除标准

  • For the non-ISR group, the patients underwent follow-up angiography less than 6 months away from stent implanting.

结局指标

主要结局

In-stent restenosis

时间窗: 6-24months after stent implanting

次要结局

  • target lesion revascularization (TLR)(6-24months after stent implanting)
  • re-myocardial infarction(6-24months after stent implating)

研究者

发起方
Shanghai Zhongshan Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验